Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.
The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
Studies point to strategies to reduce disparities, improve outcomes and support shared decision-making.
Screening high-risk groups could improve the survival of patients who develop myeloma.
Kellie Smith, 52, lives in Austin with her husband and child. She has multiple myeloma.
Powell had received treatment for multiple myeloma, which can lead to poorer response to COVID-19 vaccines.
African Americans are twice as likely to be diagnosed with multiple myeloma as white people, but lag in treatment gains.
Hospitals are filling up with COVID-19 patients and other medical conditions are going untreated.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
These findings, however, may reflect regional attitudes in Utah and the surrounding area.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.